Referred to the House Committee on Energy and Commerce.
This bill amends the Public Health Service Act to add new requirements for State plans tied to Substance Use Prevention, Treatment, and Recovery Services block grants. States would have to describe in their plans the types of drugs available for medication-assisted treatment (MAT), the MAT programs or protocols the State uses for diversion and misuse prevention and enforcement, data on misuse of drugs used for MAT (including mixing with other prescription drugs), and data on drug screening protocols in the State system of care, including protocols for patients receiving MAT.
Progressive is most worried that reporting on diversion and screening could lead to punitive practices or barriers to MAT access; conservatives emphasize using information to prevent diversion and enforce program integrity.
Relative to its intended legislative type, this bill is a narrowly focused statutory amendment that clearly identifies additional categories of information States must include in Substance Use Prevention, Treatment, and Recovery Services block grant plans, but it provides limited implementation detail and omits fiscal and definitional scaffolding.
This bill amends the Public Health Service Act to add new requirements for State plans tied to Substance Use Prevention, Treatment, and Recovery Services block grants.
States would have to describe in their plans the types of drugs available for medication-assisted treatment (MAT), the MAT programs or protocols the State uses for diversion and misuse prevention and enforcement, data on misuse of drugs used for MAT (including mixing with other prescription drugs), and data on drug screening protocols in the State system of care, including protocols for patients receiving MAT.
The change is a reporting and plan-content requirement for State grant submissions under section 1932(b)(1)(A).
On content alone, this is a modest, administratively focused change with low fiscal impact — characteristics that historically make passage easier. However, the subject (MAT) has some policy sensitivity and the bill lacks formal compromise mechanics; as a standalone measure it may be stalled or folded into larger health or appropriations legislation. The absence of funding or explicit privacy/implementation guidance creates additional friction points for enactment.
Relative to its intended legislative type, this bill is a narrowly focused statutory amendment that clearly identifies additional categories of information States must include in Substance Use Prevention, Treatment, and Recovery Services block grant plans, but it provides limited implementation detail and omits fiscal and definitional scaffolding.
Progressive is most worried that reporting on diversion and screening could lead to punitive practices or barriers to MAT access; conservatives emphasize using information to prevent diversion and enforce program integrity.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressive is most worried that reporting on diversion and screening could lead to punitive practices or barriers to MAT access; conservatives emphasize using information to prevent diversion and enforce program integr…
A mainstream liberal would likely view the bill as a mixed measure: useful for improving transparency about MAT delivery and misuse, but potentially risky if reporting or screening requirements are used to restrict access or stigmatize patients.
Liberals generally support MAT as evidence-based treatment and would want assurances that the bill's emphasis on diversion, misuse, and screening does not lead to punitive practices, loss of confidentiality, or barriers to care.
They would favor the bill if it is paired with protections for patients, funding to support data collection without cutting services, and clear limits on using reports to criminalize or restrict MAT access.
A centrist/moderate would likely see the bill as a reasonable accountability and data-improvement measure linked to federal grants, valuing better information for policymaking while noting implementation and cost concerns.
They would appreciate the focus on diversion and misuse data as a means to improve program integrity and patient safety, but would want clarity that the requirements are reporting obligations rather than mandates that change clinical practice.
Moderates will generally support it if the administrative burden is manageable and privacy/confidentiality and non-punitive use of data are assured.
A mainstream conservative would likely view the bill favorably as a measure to increase accountability, combat diversion and misuse of MAT drugs, and ensure federal funds support effective treatment programs.
They may welcome transparency about which MAT drugs are used and how states prevent diversion, seeing it as a tool to protect communities and program integrity.
Conservatives may also be wary of adding federal reporting mandates that increase bureaucracy, but many will see oversight tied to block grants as acceptable if it strengthens enforcement against misuse.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, this is a modest, administratively focused change with low fiscal impact — characteristics that historically make passage easier. However, the subject (MAT) has some policy sensitivity and the bill lacks formal compromise mechanics; as a standalone measure it may be stalled or folded into larger health or appropriations legislation. The absence of funding or explicit privacy/implementation guidance creates additional friction points for enactment.
The bill has not accumulated any surfaced votes yet.
Progressive is most worried that reporting on diversion and screening could lead to punitive practices or barriers to MAT access; conservat…
On content alone, this is a modest, administratively focused change with low fiscal impact — characteristics that historically make passage…
Relative to its intended legislative type, this bill is a narrowly focused statutory amendment that clearly identifies additional categories of information States must include in Substance Use Prevention, Treatment, and…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.